GSR
Glutathione reductase, mitochondrial
As of the edition of 20 October 2026, GSR (glutathione reductase, mitochondrial, UniProt P00390) has 2 drugs tested at it and 6 companies on the list, 0 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P00390
- How well studied
- Drug target: an approved drug acts on it
- Solved structures
- 27
- Disease areas
- Cancer; Immune system; Blood and lymph; Nervous system; Heart and blood vessels; Infections; Skin and connective tissue; Urinary and reproductive
- Registered trials of its drugs
- 201
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Carmustine | Marketed | Phase 3 | none listed |
| Oxiglutatione | Marketed | Phase 4 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 2 |
| Engaged | 4 |
| Total on the list | 6 |
| Company | Route |
|---|---|
| Alcon | Route B |
| Nobelpharma | Route B |
The other 4 companies at GSR
In the product6 companies in all; 4 are not named here, and no score is.
See the 6 companies at GSR, ranked, with the facts behind eachRequest access. Nothing is shown until you do.